M&A Deal Summary

Dechra Pharmaceuticals Acquires Invetx

On July 18, 2024, Dechra Pharmaceuticals acquired life science company Invetx from Eight Roads for 520M USD

Acquisition Highlights
  • This is Dechra Pharmaceuticals’ 14th transaction in the Life Science sector.
  • This is Dechra Pharmaceuticals’ largest (disclosed) transaction.
  • This is Dechra Pharmaceuticals’ 5th transaction in the United States.
  • This is Dechra Pharmaceuticals’ 1st transaction in Massachusetts.

M&A Deal Summary

Date 2024-07-18
Target Invetx
Sector Life Science
Buyer(s) Dechra Pharmaceuticals
Sellers(s) Eight Roads
Deal Type Add-on Acquisition
Deal Value 520M USD
Advisor(s) BofA Securities (Financial)
Latham & Watkins (Legal)

Target

Invetx

Boston, Massachusetts, United States
Invetx has built an integrated, best-in-class discovery, development, and manufacturing platform to create fully species-specific, optimized, and half-life extended product candidates. Invetx was founded in 2018 and is based in Boston, Massachusetts.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Dechra Pharmaceuticals

Northwich, United Kingdom

Category Company
Founded 1997
Sector Life Science
Revenue 682M GBP (2022)
DESCRIPTION

Dechra Pharmaceuticals is an international specialist in veterinary pharmaceuticals and related products business. Its expertise is in the development, manufacturing, sales, and marketing of quality products exclusively for veterinarians worldwide. The company's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. Dechra Pharmaceuticals was founded in 1997 and is based in Northwich, United Kingdom.


DEAL STATS #
Overall 16 of 16
Sector: Life Science M&A 14 of 14
Type: Add-on Acquisition M&A Deals 14 of 14
State: Massachusetts M&A 1 of 1
Country: United States M&A 5 of 5
Year: 2024 M&A 1 of 1
Size (of disclosed) 1 of 12
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-08-30 Med-Pharmex

Pomona, California, United States

Med-Pharmex is a manufacturer of pharmaceutical products for the animal health market which includes companion and food-producing animals. Med-Pharmex was founded in 1983 and is based in Pomona, California.

Buy -

Seller(S) 1

SELLER

Eight Roads

Investor Investor Investor Investor Investor


Category Private Equity Firm
Founded 1969
PE ASSETS 11.0B USD
Size Mega
Type Sector Focused
DESCRIPTION

Eight Roads is a private investment firm focused on a variety of investment opportunities across the US, Europe, and Asia. The Firm is divided into several investment strategies including venture, principal investing, and real estate. Within the principal investments group, Eight Roads backs established growth businesses with long-term capital. Eight Roads does not have any sector preferences, but has experience in fintech, business services, and healthcare. Eight Roads is based in London.


DEAL STATS #
Overall 110 of 124
Sector: Life Science M&A 50 of 51
Type: Add-on Acquisition M&A Deals 49 of 59
State: Massachusetts M&A 27 of 29
Country: United States M&A 60 of 67
Year: 2024 M&A 4 of 9
Size (of disclosed) 6 of 23
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2024-06-25 Reveal

Paris, France

Reveal is the free platform for Partnership, Marketing, and Sales teams to generate revenue through their ecosystem. Reveal is based in Paris, France.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2024-07-23 Planck

New York, New York, United States

Planck is a commercial insurance data platform, built to enable insurers to instantly and accurately underwrite any business. Planck's technology platform aggregates and mines massive datasets, using the latest advances in artificial intelligence to automatically generate and deliver key insights customized to the commercial underwriting process. Planck was founded in 2016 and is based in New York City.

Sell -